Project ALS is pleased to share that the FDA has approved the drug edaravone – the first approved ALS treatment in over 20 years.

Edaravone, a free radical scavenger, appears to react with nerve-damaging compounds generated as part of the disease process. After six months of treatment, on top of standard-of-care, data showed the intravenous drug reduced the rate of functional decline in patients by about a third.

Read more